NURSING NEWBIE ACADEMY
LEARN TO THINK LIKE A NURSE
Patient List
NSJH β€’ VIRTUAL HOSPITAL

Maya Bennett

MRN 681429 β€’ Hypopituitarism
Patient profile image for Maya Bennett
Age / Gender
36 β€’ Woman
Race
Black / African American
Allergies
Penicillin β€’ hives
Code Status
Full Code
Admitting Diagnosis
Hypopituitarism with suspected adrenal crisis
Chief Complaint
Repeated vomiting, profound weakness, and near-syncope
Provider
Dr. Zoe Langston, MD
Location
Emergency Department β€’ ED-12
01

Admission Snapshot

Chief Complaint

β€œI keep throwing up, and I can't keep my steroid pills down. I'm so weak I can barely stand. This isn't the showβ€”please help me.”

Maya arrives by EMS after nearly collapsing beside a prop coffin inside a Halloween haunted attraction. She reports repeated vomiting, worsening weakness, and dizziness when attempting to stand.

Patient Profile

DOB: 04/17/1990 β€’ 5 ft 6 in (167.6 cm) β€’ 143 lb (64.9 kg) β€’ BMI 23.1

Isolation Status: Standard Precautions at arrival; reassess if infectious gastroenteritis is suspected.

Medical History

  • Transsphenoidal resection of a nonfunctioning pituitary macroadenoma in 2022.
  • Postoperative hypopituitarism with ACTH deficiency causing secondary adrenal insufficiency.
  • Central hypothyroidism following pituitary surgery.
  • No known arginine vasopressin deficiency (central diabetes insipidus).
  • No known diabetes mellitus, heart failure, or chronic kidney disease.

Home Medications

  • Hydrocortisone 10 mg PO at 0800 and 5 mg PO at 1500 β€” secondary adrenal insufficiency. Last dose retained without vomiting: 10/30/2026 at 1500. Reports vomiting approximately 10 minutes after the morning dose on 10/31; absorption is uncertain.
  • Levothyroxine 100 mcg PO every morning β€” central hypothyroidism. Reports several recent missed doses. Today's dose was taken shortly before vomiting; absorption is uncertain.
  • Hydrocortisone sodium succinate 100 mg IM emergency kit β€” prescribed emergency rescue medication. Kit at home is expired. Maya has never practiced preparing or administering it. No rescue dose was given before arrival.

Recent History

Maya, an elementary-school librarian, volunteered as a Victorian ghost in the festival's haunted reading room. An open coffin stood between shelves of dust-covered books. A recording beneath its lining whispered, β€œDon't let them bury me,” while concealed speakers played scratching sounds from inside the lid.

She had been vomiting since overnight after a household contact developed a brief gastrointestinal illness. She attempted her morning medications but vomited about 10 minutes later. She did not use her sick-day plan, contact her endocrine team, or obtain an emergency injection before attending the event. Her scheduled afternoon hydrocortisone dose was also missed.

During her shift, she became sweaty, shaky, and too weak to remain standing. She slid to the floor beside the coffin and reached toward passing guests. They stepped around her, laughing, while the recorded voice continued begging from inside the empty box.

A friend offered candy, but Maya vomited again. When the friend leaned closer, Maya whispered, β€œThis isn't the show. Please help me.” The friend stopped the attraction and called EMS.

No witnessed fall, head strike, seizure, alcohol use, sudden severe headache, or new visual change. The precipitating illness has not yet been confirmed.

Emergency Contact

Elena Bennett β€’ Sister

589-216-XXXX

Insurance

Commercial employer-sponsored PPO

Current Care Status

10/31/2026 β€’ Emergency Department, ED-12. Urgent evaluation and stabilization for suspected adrenal crisis are underway. Full Code.

Dr. Zoe Langston, MD, is the admitting emergency provider. Critical care consultation with Dr. Nadia Wells, MD, and endocrinology consultation with Dr. Fatima Almasi, NP, have been requested.

02

Patient Timeline

2000 Emergency Department β€’ ED-12
The Ghost Who Asked for Help

Maya arrives pale, diaphoretic, and slow to answer after repeated vomiting and near-collapse at the haunted attraction. Initial assessment identifies hypotension and a critically low bedside glucose.

10/31/2026 β€’ 2000 β€’ Updates through 2105
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Chief Complaint

β€œI keep throwing up my steroid pills. I feel like I'm going to pass out. Please don't leave me here.”

History of Present Illness

Maya is a 36-year-old woman with postoperative hypopituitarism, secondary adrenal insufficiency, and central hypothyroidism. EMS transported her after near-collapse beside a prop coffin at a Halloween haunted attraction.

She has had repeated nonbloody vomiting since overnight, poor oral intake, progressive weakness, and dizziness when standing. A household contact recently had a brief gastrointestinal illness. Maya reports no diarrhea at present.

Last hydrocortisone dose retained without vomiting was 5 mg on 10/30 at 1500. She vomited approximately 10 minutes after today's morning medications, making absorption uncertain, and missed her afternoon hydrocortisone dose. She did not implement a sick-day plan or administer an emergency injection. Her rescue kit is expired and she has never practiced using it.

At the attraction, her pallor, trembling, and delayed responses were initially mistaken for part of her ghost performance. A friend stopped the attraction after Maya whispered that she needed help. No witnessed fall, head strike, loss of consciousness, or seizure.

Initial bedside glucose is 42 mg/dL and BP is 78/44 mmHg. She is drowsy but follows commands and protects her airway. Emergency treatment was initiated without waiting for endocrine laboratory results.

Past Medical History

  • Nonfunctioning pituitary macroadenoma, resected transsphenoidally in 2022.
  • Postoperative ACTH deficiency with secondary adrenal insufficiency.
  • Central hypothyroidism.
  • No known arginine vasopressin deficiency or prior desmopressin use.
  • No known diabetes mellitus, heart failure, or chronic kidney disease.
  • Penicillin allergy: hives.

Family History

  • No known familial pituitary disorder or adrenal insufficiency.
  • Further history limited during initial resuscitation.

Social History

  • Elementary-school librarian.
  • Volunteering at a Halloween haunted attraction.
  • Recent household exposure to a gastrointestinal illness.
  • No alcohol or recreational drug use reported tonight.
  • Sister Elena Bennett is her emergency contact.

Home Medications

  • Hydrocortisone 10 mg PO at 0800 and 5 mg PO at 1500.
  • Levothyroxine 100 mcg PO every morning; several recent missed doses.
  • Hydrocortisone sodium succinate 100 mg IM emergency kit; expired and not used.

Review of Systems

Constitutional: Profound weakness, poor intake, and sweating.

Neurologic: Lightheadedness and slowed responses. No sudden severe headache, seizure, or focal weakness reported.

Eyes: No new visual loss or diplopia.

Cardiovascular: Near-syncope when standing. No chest pain.

Respiratory: No cough or dyspnea.

Gastrointestinal: Repeated vomiting and diffuse abdominal discomfort. No hematemesis, melena, or current diarrhea.

Genitourinary: Reports urinating less than usual. No dysuria.

Physical Examination

General: Acutely ill, diaphoretic, and visibly weak. Residual white theatrical makeup is present along the hairline.

Neurologic: Initial GCS 14: E3, V5, M6. Opens eyes to voice, answers appropriately after a delay, and follows commands. Pupils equal and reactive. No focal motor deficit.

Cardiovascular: HR 116/min, regular. Initial BP 78/44 mmHg, MAP 55. Extremities cool; capillary refill approximately four seconds.

Respiratory: RR 22/min. Lungs clear. SpOβ‚‚ 98% on room air. Airway protected.

Abdomen: Soft with mild diffuse tenderness. No guarding, rebound, or distention.

Skin and Mucosa: Diaphoretic with dry oral mucosa. No new generalized hyperpigmentation identified.

Labs

Bedside glucose at 2001 is 42 mg/dL. Blood collected at 2003, before hydrocortisone: sodium 118 mEq/L, potassium 4.1 mEq/L, chloride 86 mEq/L, bicarbonate 20 mEq/L, BUN 26 mg/dL, creatinine 1.2 mg/dL, serum glucose 44 mg/dL, measured serum osmolality 251 mOsm/kg, and lactate 2.8 mmol/L.

WBC 8.9 Γ— 10Β³/Β΅L, hemoglobin 13.1 g/dL, and platelets 244 Γ— 10Β³/Β΅L. Free T4 is 0.58 ng/dL with TSH 1.1 mIU/L. Cortisol and ACTH are pending. Serum pregnancy test is negative.

Sodium 118 and glucose 44 are critical results. The normal potassium does not exclude secondary adrenal insufficiency. TSH alone cannot assess adequacy of treatment for her central hypothyroidism.

Diagnostics

ECG at 2007 shows sinus tachycardia without acute ischemic changes; QTc 435 ms. Urinalysis is pending. No immediate neuroimaging ordered because she has no sudden severe headache, new visual deficit, or focal examination finding.

Assessment

  • Suspected adrenal crisis due to inadequate effective glucocorticoid replacement during an acute vomiting illness.
  • Hypotension with impaired perfusion and probable volume depletion.
  • Symptomatic hypoglycemia.
  • Severe hypotonic hyponatremia, likely multifactorial in the setting of cortisol deficiency and vomiting.
  • Central hypothyroidism with low free T4; recent adherence and absorption problems.
  • Possible infectious gastroenteritis. Continue evaluation for other precipitating illness if clinical findings warrant.

Plan

  • Hydrocortisone sodium succinate 100 mg IV immediately, followed by 50 mg IV every six hours beginning 11/01 at 0204. Reassess regimen with endocrinology within 24 hours.
  • Dextrose 10% 250 mL IV over 15 minutes for symptomatic hypoglycemia. Repeat bedside glucose at completion and every 15 minutes until stable.
  • Normal saline 1,000 mL IV over one hour, followed by reassessment before additional fluid. Monitor respiratory status and urine output.
  • Continuous ECG and pulse oximetry. BP and neurologic checks every 15 minutes during initial instability.
  • Repeat sodium at 2200, then every two hours initially. Monitor closely for rapid correction or a sudden increase in urine output after steroids.
  • Initial sodium-correction goal is 4–6 mEq/L over 24 hours; avoid exceeding 8 mEq/L in any 24-hour period. Notify provider immediately for a rise greater than 2 mEq/L between two-hour checks.
  • No seizure or coma at present. Hypertonic saline is not ordered currently; reassess immediately for severe neurologic symptoms or deterioration.
  • Hold home oral hydrocortisone while receiving IV stress-dose treatment. Defer levothyroxine until glucocorticoid coverage is established and oral tolerance is reassessed.
  • Contact and Standard Precautions pending assessment of possible infectious gastroenteritis.
  • Critical care and endocrinology consultations. Admit to ICU for frequent metabolic and hemodynamic monitoring.

Reassessment at 2105

After dextrose, hydrocortisone, and the 1,000 mL saline bolus, Maya is awake with GCS 15. BP 92/56 mmHg, MAP 68, HR 102/min. Bedside glucose at 2100 is 86 mg/dL. Weakness persists. Repeat sodium is due at 2200. Additional fluid decisions remain under bedside reassessment.

Provider Information

Dr. Zoe Langston, MD
Emergency Medicine

10/31/2026 β€’ 2000 β€’ Updates through 2105
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Nursing Progress Note

Arrived by EMS wearing a Victorian-style ghost costume with dried emesis on the sleeve. Patient opens eyes to voice, follows commands, and answers after a delay. States, β€œThey thought I was supposed to be on the floor.” Reports inability to retain steroid medication. Initial BP 78/44 mmHg, HR 116/min, and bedside glucose 42 mg/dL. Dr. Langston notified immediately.

Placed supine with assisted positioning, continuous monitoring, suction available, and fall precautions. Oral intake withheld during drowsiness and active nausea. Two peripheral IVs established. Blood collected at 2003 without delaying treatment.

Dextrose 10% 250 mL started at 2003 and completed at 2018. Hydrocortisone 100 mg IV given at 2004. Normal saline 1,000 mL started at 2004 and completed at 2104. Separate IV access used for simultaneous therapies. Both sites remain without swelling, pain, blanching, or leakage.

Bedside glucose increased to 104 mg/dL at 2018 and was 92 mg/dL at 2033. Patient became more alert and sweating decreased. Additional scheduled reassessments at 2048 and 2100 were 88 and 86 mg/dL. No recurrent hypoglycemic symptoms observed.

Foley inserted at 2010 for accurate urine measurement during hemodynamic instability. Initial bladder return was 15 mL. An additional 20 mL drained from 2010–2105, a 55-minute collection interval. Initial bladder return is recorded separately and is not treated as an hourly output rate.

Ondansetron 4 mg IV given at 2012. No further emesis observed through 2105. Contact and Standard Precautions initiated for possible infectious gastrointestinal illness. Sister Elena updated with patient permission.

Critical sodium result of 118 mEq/L reported to Dr. Langston. Repeat specimen due at 2200. At 2105, patient is awake and oriented Γ—4, BP 92/56 mmHg, MAP 68, HR 102/min, and lungs remain clear. ICU admission pending bed assignment.

10/31/2026 β€’ 2045
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Endocrinology Consultation

Reason for Consultation

Postoperative hypopituitarism with suspected adrenal crisis, hypoglycemia, and severe hyponatremia.

Impression

Known ACTH deficiency with interruption of effective glucocorticoid replacement during an acute vomiting illness. Presentation strongly supports adrenal crisis. Treatment should not await cortisol or ACTH results.

Potassium is within range, consistent with generally preserved aldosterone function in secondary adrenal insufficiency. Low free T4 with a non-elevated TSH is compatible with her established central hypothyroidism.

Recommendations

  • Continue parenteral stress-dose hydrocortisone. Initial 100 mg dose given at 2004; subsequent 50 mg IV every six hours.
  • Continue glucose monitoring and individualized fluid replacement with frequent reassessment.
  • Follow sodium every two hours initially. Cortisol replacement may restore water excretion and accelerate sodium correction.
  • Track urine output closely and notify provider for abrupt polyuria or unexpectedly rapid sodium rise.
  • Do not interpret a normal TSH as adequate replacement in central hypothyroidism. Resume thyroid replacement only after glucocorticoid coverage and clinical review.
  • Fludrocortisone is not routinely indicated for this established secondary adrenal deficiency.
  • After stabilization, provide a written sick-day plan, replacement emergency kit, injection training, and medical-alert identification guidance.

Consulting Provider

Dr. Fatima Almasi, NP
Endocrinology Nurse Practitioner

Current Provider Orders
Orders reviewed through 2105 on 10/31/2026. Completed emergency treatments remain visible for continuity.
Order Type Order Details Priority Ordered By Status Comments
Admission Admit to ICU for adrenal crisis, hypotension, hypoglycemia, and severe hyponatremia. STAT Dr. Zoe Langston, MD Pending bed assignment Critical care consultation requested with Dr. Nadia Wells, MD.
Medication Hydrocortisone sodium succinate 100 mg IV once immediately for suspected adrenal crisis. STAT Dr. Zoe Langston, MD Given at 2004 Do not delay for endocrine test results.
Medication Hydrocortisone sodium succinate 50 mg IV every six hours, beginning 11/01 at 0204. Reassess within 24 hours. Scheduled Dr. Zoe Langston, MD Active Subsequent schedule: 0204, 0804, 1404, and 2004. Do not administer home oral hydrocortisone concurrently unless specifically ordered.
Medication Dextrose 10% 250 mL IV over 15 minutes once for symptomatic hypoglycemia. STAT Dr. Zoe Langston, MD Completed at 2018 Contains 25 g dextrose. Started at 2003.
Medication / Rescue For recurrent bedside glucose <70 mg/dL while unable to take oral carbohydrate: dextrose 10% 125 mL IV over 10 minutes; recheck glucose 15 minutes after completion. May repeat once if still <70 mg/dL. PRN emergency Dr. Zoe Langston, MD Active for 24 hours; not used Notify provider immediately for recurrence, persistent symptoms, or need for repeat treatment. Reassess need for continuous dextrose support. Expires 11/01 at 2000.
IV Fluid Normal saline 1,000 mL IV over one hour for hypotension and volume depletion. STAT Dr. Zoe Langston, MD Completed at 2104 Started at 2004. Reassess before additional fluids; no automatic repeat bolus ordered.
Medication Ondansetron 4 mg IV every eight hours PRN nausea or vomiting for 24 hours. PRN Dr. Zoe Langston, MD Active Given at 2012. Next eligible 11/01 at 0412. Expires 11/01 at 2012.
Medication Reconciliation Hold home oral hydrocortisone during IV stress-dose therapy. Immediate Dr. Zoe Langston, MD Active hold Prevent duplicate replacement. Resume oral regimen only with a new plan.
Medication Reconciliation Temporarily defer home levothyroxine pending glucocorticoid coverage, oral tolerance, and endocrine review. Immediate Dr. Zoe Langston, MD Held pending reassessment No extra oral dose or IV loading dose ordered.
Monitoring Continuous ECG and pulse oximetry. BP and neurologic assessments every 15 minutes during instability. Continuous / Every 15 minutes Dr. Zoe Langston, MD Active Notify for MAP <65 mmHg, declining consciousness, seizure, or new focal deficit.
Glucose Monitoring Bedside glucose at completion of initial dextrose and every 15 minutes until two consecutive readings β‰₯70 mg/dL with symptom improvement; then hourly. Timed / PRN Dr. Zoe Langston, MD Active Required checks at 2018 and 2033 met criteria. Additional checks at 2048 and 2100 completed. Continue hourly from 2100 and PRN symptoms.
Laboratory CBC, metabolic panel, serum osmolality, lactate, cortisol, ACTH, free T4, TSH, and serum pregnancy test. STAT Dr. Zoe Langston, MD Collected 2003; cortisol and ACTH pending Pretreatment endocrine samples obtained without delaying hydrocortisone.
Laboratory Sodium at 2200, then every two hours until frequency reassessed. Repeat metabolic panel and lactate at 2200. Timed Dr. Zoe Langston, MD Active Sodium goal rise 4–6 mEq/L over 24 hours; avoid >8 mEq/L in any 24 hours. Notify for rise >2 mEq/L between two-hour checks or abrupt polyuria.
Procedure / Monitoring Insert Foley for accurate hourly urine measurement during shock. STAT Dr. Zoe Langston, MD Inserted at 2010; monitoring active Record initial return separately. Output target β‰₯0.5 mL/kg/hr, approximately 32 mL/hr at 64.9 kg. Reassess catheter need daily.
Diagnostic 12-lead ECG and urinalysis. STAT Dr. Zoe Langston, MD ECG completed; urinalysis pending ECG at 2007: sinus tachycardia, no acute ischemic changes.
Isolation Contact and Standard Precautions for possible infectious gastroenteritis. Immediate Dr. Zoe Langston, MD Active Reassess with clinical course and infection-prevention guidance.
Diet / Activity NPO during initial instability and vomiting. Bed rest with assisted repositioning, aspiration precautions, and fall precautions. Immediate Dr. Zoe Langston, MD Active Reassess oral intake as alertness and nausea improve.
Consultation Endocrinology and critical care consultation. Urgent Dr. Zoe Langston, MD Endocrinology completed; critical care pending Dr. Fatima Almasi, NP, evaluated at 2045. Dr. Nadia Wells, MD, requested for ICU care.
Vital Signs and Perfusion
Initial assessment at 2000; reassessment at 2105. H* and L* indicate values outside the displayed reference or target. Initial bladder return is separate from timed urine production.
Assessment 2000 β€’ Arrival 2105 β€’ Reassessment Reference / Target
Temperature 37.8Β°C / 100.0Β°F H* 37.6Β°C / 99.7Β°F H* 36.5–37.5Β°C / 97.7–99.5Β°F
Heart Rate 116/min H* 102/min H* 60–100/min
Respiratory Rate 22/min H* 20/min 12–20/min
Blood Pressure 78/44 mmHg L* 92/56 mmHg β€’ Diastolic L* General adult reference: 90–119 / 60–79 mmHg; interpret with perfusion and MAP
Mean Arterial Pressure 55 mmHg L* 68 mmHg Perfusion target β‰₯65 mmHg
SpOβ‚‚ 98% on room air 99% on room air 95–100%
Pain 4/10 β€’ Diffuse abdominal discomfort 2/10 β€’ Abdominal discomfort 0–10 scale; individualized comfort goal
Glasgow Coma Scale 14 L* β€’ E3, V5, M6 15 β€’ E4, V5, M6 15
Capillary Refill Approximately 4 seconds H* Approximately 3 seconds H* ≀2 seconds
Urine Output Not yet measured Initial Foley return: 15 mL at 2010. Additional urine: 20 mL over 55 minutes, 2010–2105; below target for the timed interval. β‰₯0.5 mL/kg/hr; approximately 32 mL/hr at 64.9 kg
Initial Laboratory Results
Blood collected at 2003 before hydrocortisone. H* = high; L* = low relative to the displayed range. Low glucose is clinically significant regardless of fasting status.
Laboratory Test Result Reference / Context
WBC 8.9 5–11 Γ— 10Β³/Β΅L
Hemoglobin 13.1 12–15 g/dL β€’ Female
Platelets 244 150–450 Γ— 10Β³/Β΅L
Sodium 118 mEq/L L* β€’ Critical 135–145 mEq/L
Potassium 4.1 mEq/L 3.5–5.0 mEq/L
Chloride 86 mEq/L L* 95–105 mEq/L
Bicarbonate 20 mEq/L L* 22–29 mEq/L
Anion Gap 12 mEq/L 8–12 mEq/L
BUN 26 mg/dL H* 10–20 mg/dL
Creatinine 1.2 mg/dL 0.6–1.2 mg/dL; prior baseline not yet available
Serum Glucose 44 mg/dL L* β€’ Critical NSJH fasting reference: 60–100 mg/dL. Fasting status unknown. Value is hypoglycemic regardless of fasting.
Measured Serum Osmolality 251 mOsm/kg L* 275–295 mOsm/kg
Lactate 2.8 mmol/L H* 0.5–2.2 mmol/L
Free T4 0.58 ng/dL L* 0.8–1.8 ng/dL
TSH 1.1 mIU/L 0.4–4.0 mIU/L. A value within range does not exclude central hypothyroidism.
Cortisol Pending Pretreatment sample. Interpret with timing, prior steroid exposure, and assay context. Do not await result to treat.
ACTH Pending Pretreatment sample; assay-specific interpretation
Serum Pregnancy Test Negative Negative
Urinalysis Pending Result not yet available
Bedside Glucose Response
Time Glucose Clinical Context
2001 42 mg/dL L* β€’ Critical Before dextrose; diaphoretic and drowsy.
2018 104 mg/dL At completion of 25 g IV dextrose; alertness improving.
2033 92 mg/dL Second consecutive reading β‰₯70 mg/dL with symptom improvement.
2048 88 mg/dL Additional reassessment; no recurrent symptoms.
2100 86 mg/dL Continue hourly checks and PRN symptoms. Post-dextrose values are not fasting specimens.
Diagnostic Studies
  • 2007 β€’ 12-lead ECG: Sinus tachycardia. No acute ischemic changes. QTc 435 ms.
  • Pretreatment cortisol and ACTH: Collected at 2003; pending. Emergency glucocorticoid treatment was not delayed for results.
  • Thyroid studies: Low free T4 with non-elevated TSH in a patient with established central hypothyroidism. TSH is not an adequate standalone replacement target.
  • Serum osmolality: Low at 251 mOsm/kg, supporting hypotonic hyponatremia. Repeat sodium is scheduled for 2200.
  • Urinalysis: Specimen submitted; result pending.
  • Neuroimaging: Not currently ordered. No sudden severe headache, visual change, or focal deficit. Reassess urgently if these findings develop.
Significant Events
  • 2000: Arrived in ED-12 with hypotension, diaphoresis, and delayed responses. Dr. Langston at bedside.
  • 2001: Bedside glucose 42 mg/dL. Emergency hypoglycemia treatment ordered.
  • 2003: Blood specimens collected, including cortisol and ACTH. Dextrose 10% 250 mL started.
  • 2004: Hydrocortisone 100 mg IV administered. Normal saline 1,000 mL bolus started through separate IV access.
  • 2007: ECG completed: sinus tachycardia.
  • 2010: Foley inserted for accurate urine measurement. Initial return 15 mL, recorded separately from subsequent urine production.
  • 2012: Ondansetron 4 mg IV administered.
  • 2018: Dextrose infusion completed. Bedside glucose 104 mg/dL. Patient more alert.
  • 2033: Bedside glucose 92 mg/dL. Symptom improvement maintained.
  • 2045: Endocrinology consultation completed by Dr. Fatima Almasi, NP. Frequent sodium and urine-output monitoring emphasized.
  • 2048: Additional bedside glucose 88 mg/dL.
  • 2100: Bedside glucose 86 mg/dL. Continue hourly checks.
  • 2104: Normal saline 1,000 mL bolus completed.
  • 2105: BP 92/56 mmHg, MAP 68. GCS 15. Additional urine since Foley insertion: 20 mL over 55 minutes. ICU bed assignment pending. Repeat sodium and metabolic assessment due at 2200.
Clinical Judgment

Review Maya's hormone-replacement history, initial perfusion, glucose, and sodium before answering.

Answer & Rationale

Maya has known ACTH deficiency and cannot reliably retain her glucocorticoid replacement during an acute vomiting illness. Hypotension, poor perfusion, profound weakness, hypoglycemia, and hyponatremia strongly support adrenal crisis in this context. Priorities include airway and mental-status assessment, immediate prescribed parenteral hydrocortisone, IV dextrose for symptomatic hypoglycemia, and isotonic fluid resuscitation with reassessment. These treatments address threats occurring together and should be organized promptly using available access.

Cortisol and ACTH may be collected before treatment if doing so causes no delay, but results are not required before emergency therapy. Waiting would prolong cortisol deficiency and impaired perfusion. A normal potassium does not exclude this diagnosis because aldosterone function is usually preserved in secondary adrenal insufficiency. Continue close monitoring after the initial response; improvement in glucose alone does not resolve the underlying crisis.

Answer & Rationale

Cortisol deficiency impairs free-water excretion, and volume depletion can further promote water retention. Hydrocortisone and restoration of volume may reverse these effects and produce increased urine output with a rapid sodium rise. Follow the ordered sodium measurements and distinguish initial bladder return from timed urine production. Report unexpectedly rapid correction or abrupt polyuria promptly so the provider can reassess therapy. Excessive correction of severe hyponatremia can cause serious neurologic injury.

Central hypothyroidism results from pituitary dysfunction, so TSH can be within the laboratory range despite a low free T4. Thyroid replacement decisions therefore require free T4 and clinical assessment rather than TSH alone. Glucocorticoid coverage takes priority because thyroid hormone can increase cortisol requirements and clearance, worsening untreated adrenal insufficiency. Resume Maya's thyroid medication under the documented endocrine plan after steroid coverage and oral tolerance are established.

Please answer both questions before submitting.
0000 Intensive Care Unit β€’ Room 410
The Quiet After the Screaming

Maya is awake, her blood pressure has improved, and glucose remains above the hypoglycemia threshold. During the last hour, however, urine output increases sharply while her sodium continues to rise.

11/01/2026 β€’ 0000 β€’ Updates through 0010
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Chief Complaint

β€œI feel more awake, but I'm still weak. I can't believe they thought I was acting.”

Interval History

Maya was transferred to ICU Room 410 at 2130 for adrenal crisis with hypotension, symptomatic hypoglycemia, and severe hypotonic hyponatremia.

In the ED, she received hydrocortisone 100 mg IV at 2004, dextrose 25 g IV, and normal saline 1,000 mL. A subsequent order for normal saline at 100 mL/hr began at 2110 after reassessment of persistent volume depletion. No additional bolus or vasopressor has been required.

Blood pressure and alertness improved. No additional vomiting has occurred since ondansetron at 2012. Serial bedside glucose values have remained at least 70 mg/dL without additional rescue dextrose.

Sodium increased from 118 mEq/L at 2003 to 121 at 2200 and 122 at 0000. This is a cumulative increase of 4 mEq/L in approximately four hours. The ordered 24-hour correction goal has already been reached at its lower boundary, although the maximum correction limit has not been exceeded.

Urine output increased from 60 mL during 2200–2300 to 350 mL during 2300–0000. Bedside review at 2355 prompted discontinuation of the saline infusion while blood pressure remained stable. A fresh urine specimen shows dilute urine.

Rising urine output may reflect restoration of water excretion after cortisol replacement and volume repletion. Given prior pituitary surgery, previously masked arginine vasopressin deficiency also requires consideration if hypotonic polyuria persists. A single high-output hour does not establish that diagnosis.

Past Medical History

  • Transsphenoidal resection of a nonfunctioning pituitary macroadenoma in 2022.
  • Postoperative ACTH deficiency with secondary adrenal insufficiency.
  • Central hypothyroidism.
  • No previously diagnosed arginine vasopressin deficiency or desmopressin use.
  • No known diabetes mellitus, heart failure, or chronic kidney disease.

Family History

  • No known familial pituitary disorder or adrenal insufficiency.

Social History

  • Elementary-school librarian.
  • Recent household exposure to a brief gastrointestinal illness.
  • Became acutely unwell while volunteering at a Halloween attraction.
  • Sister Elena is available to participate in medication and emergency-injection teaching.

Allergies

Penicillin β€’ hives.

Review of Systems

Constitutional: Persistent fatigue and weakness; sweating has resolved.

Neurologic: No current confusion, seizure, severe headache, or focal weakness.

Eyes: No new visual change.

Cardiovascular: No chest pain or palpitations. Has not attempted standing since ICU arrival.

Respiratory: No dyspnea.

Gastrointestinal: Nausea improved; no further vomiting or diarrhea. Mild abdominal discomfort persists.

Genitourinary: Foley present; increased measured urine output.

Physical Examination

General: Awake, conversant, and fatigued. No longer diaphoretic.

Neurologic: GCS 15. Oriented to person, place, time, and situation. Pupils equal and reactive. Strength symmetric.

Cardiovascular: HR 92/min, regular. BP 104/64 mmHg, MAP 77. Extremities warm; capillary refill approximately two seconds.

Respiratory: RR 18/min. Lungs clear. SpOβ‚‚ 99% on room air.

Abdomen: Soft with mild diffuse discomfort. No guarding or rebound.

Lines and Devices: Two peripheral IVs without infiltration. Foley draining clear, pale urine. No central or arterial line present.

Labs

Sodium: 118 mEq/L at 2003, 121 at 2200, and 122 at 0000. Current potassium 3.8 mEq/L, bicarbonate 23 mEq/L, BUN 20 mg/dL, creatinine 0.9 mg/dL, and serum glucose 83 mg/dL.

Lactate decreased from 2.8 to 1.6 mmol/L at 2200. It was not repeated at 0000. Fresh urine osmolality at 0000 is 110 mOsm/kg with specific gravity 1.003.

Pretreatment cortisol collected at 2003 returned at 1.2 mcg/dL. ACTH is 4 pg/mL. These findings support the established central adrenal deficiency in context; the random cortisol is not interpreted using a morning screening cutoff alone.

Diagnostics

Initial ECG showed sinus tachycardia. Current telemetry shows sinus rhythm. Urinalysis is negative for glucose, ketones, leukocyte esterase, and nitrites. Paired serum and urine assessments are being trended for the new diuresis.

Assessment

  • Adrenal crisis with improving perfusion after parenteral glucocorticoids and fluids.
  • Symptomatic hypoglycemia corrected; ongoing recurrence risk during limited intake.
  • Severe hypotonic hyponatremia with early sodium rise and new dilute diuresis, creating risk of excessive correction.
  • Possible recovery-related water diuresis; monitor for previously masked AVP deficiency if hypotonic polyuria persists.
  • Central hypothyroidism; glucocorticoid coverage established.
  • Acute vomiting illness, improving; infectious cause not confirmed.

Plan

  • Continue hydrocortisone 50 mg IV every six hours. First maintenance dose remains due at 0204.
  • Keep saline infusion discontinued during immediate reassessment. Do not automatically replace urine losses with saline.
  • Check sodium hourly beginning at 0100. Initial 24-hour goal remains a rise of 4–6 mEq/L from the baseline of 118; avoid exceeding 8 mEq/L in any 24 hours.
  • Notify provider immediately if sodium reaches 124 mEq/L before the next review, rises more than 1 mEq/L between hourly measurements, or urine output remains above 200 mL/hr for two consecutive hours.
  • Continue strict hourly urine measurement and document all oral and IV intake. Reassess hemodynamics and fluid balance hourly.
  • Endocrinology and nephrology review for persistent diuresis or accelerating correction. Desmopressin and electrolyte-free water would require specific specialist-directed orders; neither is currently prescribed.
  • Continue hourly bedside glucose. Use existing rescue order for recurrence and notify provider.
  • Begin measured clear liquids as tolerated. Do not impose fluid restriction or encourage unrestricted water intake without a revised plan.
  • Resume home levothyroxine 100 mcg PO at 0800 if oral medications are tolerated. Do not increase the dose based on TSH.
  • Continue Contact and Standard Precautions pending review of the vomiting illness.
  • Begin brief education when rested: vomiting-related emergency action, sick-day coverage, and replacement rescue kit.

Provider Information

Dr. Nadia Wells, MD
Critical Care Medicine

11/01/2026 β€’ 0000 β€’ Updates through 0010
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Nursing Progress Note

Received from ED at 2130. Awake and oriented Γ—4, GCS 15. Patient states she remembers reaching toward guests while the coffin recording continued asking for help. Reassured patient and explained current monitoring.

BP improved without vasopressors. At 0000, BP 104/64 mmHg, MAP 77, HR 92/min, RR 18/min, and SpOβ‚‚ 99% on room air. Extremities warm with capillary refill approximately two seconds. Lungs clear.

Normal saline at 100 mL/hr had been started in the ED at 2110 after the initial bolus. During 2300–0000, Foley output increased to 350 mL of pale urine, compared with 60 mL during the preceding hour. Dr. Wells notified at 2355. Saline discontinued at that time per order. Both peripheral IVs remain patent.

Sodium increased from 118 at 2003 to 121 at 2200 and 122 at 0000. No new headache, confusion, seizure, or focal weakness. Hourly sodium measurements ordered; next specimen due at 0100. Fresh urine sample sent for osmolality and specific gravity.

Bedside glucose at 0000 is 84 mg/dL. No recurrent diaphoresis, tremor, or altered responsiveness. No rescue dextrose required after the initial ED treatment. Next scheduled glucose check at 0100.

No further vomiting since ED treatment. Measured clear liquids now permitted; intake will be recorded. First scheduled hydrocortisone 50 mg IV dose due at 0204. Home oral hydrocortisone remains held.

Sister Elena updated with permission. Maya states, β€œI thought I just needed to get through the shift.” Explained that inability to retain steroid medication requires an emergency plan. Detailed teaching deferred until rested. Contact and Standard Precautions maintained.

11/01/2026 β€’ 0005
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Endocrinology Follow-Up

Reason for Consultation

Adrenal crisis with improving hemodynamics and new dilute diuresis during correction of severe hyponatremia.

Impression

Clinical response supports cortisol deficiency and volume depletion as major contributors. Increased water excretion after glucocorticoid replacement can accelerate sodium correction. Prior pituitary surgery also warrants monitoring for previously masked AVP deficiency. Current findings do not yet establish that diagnosis.

Recommendations

  • Continue IV stress-dose hydrocortisone; do not withhold essential steroid treatment because sodium is rising.
  • Agree with stopping saline during reassessment and increasing sodium checks to hourly.
  • Continue hourly urine output. Interpret urine concentration alongside serum sodium, osmolality, glucose, and clinical volume status.
  • Obtain nephrology input if diuresis persists or sodium approaches the correction ceiling. Do not give empiric desmopressin without a specific treatment plan.
  • Resume usual levothyroxine at 0800 if oral tolerance permits. Steroid coverage is now established. Reassess free T4 after recovery and a consistent replacement interval.
  • Replace expired rescue kit before discharge and complete hands-on injection teaching with Maya and her chosen support person.

Consulting Provider

Dr. Fatima Almasi, NP
Endocrinology Nurse Practitioner

Additional Consultation Requested

Dr. Saanvi Reddy, DO
Nephrology β€’ Review requested at 0010; consultation pending.

Current Provider Orders
Reviewed through 0010 on 11/01/2026. Earlier treatments and order changes remain visible.
Order Type Order Details Priority Ordered By Status Comments
Admission ICU care for adrenal crisis and severe hyponatremia. STAT Dr. Zoe Langston, MD Completed / ICU care active Transferred at 2130 on 10/31. Room 410; Dr. Nadia Wells attending.
Medication Hydrocortisone sodium succinate 100 mg IV once. STAT Dr. Zoe Langston, MD Given 10/31 at 2004 Initial emergency dose.
Medication Hydrocortisone sodium succinate 50 mg IV every six hours, beginning 11/01 at 0204. Reassess within 24 hours of initiation. Scheduled Dr. Zoe Langston, MD Active First maintenance dose not yet due. Schedule: 0204, 0804, 1404, 2004. Continue pending endocrine-directed revision.
Medication Dextrose 10% 250 mL IV over 15 minutes once. STAT Dr. Zoe Langston, MD Completed 10/31 at 2018 25 g dextrose; no repeat rescue required.
Medication / Rescue If bedside glucose <70 mg/dL and unable to take oral carbohydrate: dextrose 10% 125 mL IV over 10 minutes. Recheck 15 minutes after completion; may repeat once if still <70 mg/dL. PRN emergency Dr. Zoe Langston, MD Active; not used Notify provider immediately for recurrence or repeat treatment. Expires 11/01 at 2000. If awake and able to swallow, obtain and follow the oral-treatment plan.
IV Fluid Normal saline 1,000 mL IV over one hour. STAT Dr. Zoe Langston, MD Completed 10/31 at 2104 Initial resuscitation bolus.
IV Fluid Normal saline 100 mL/hr, started after bedside reassessment. Routine / Reassess Dr. Zoe Langston, MD Started 10/31 at 2110; discontinued at 2355 Stopped by Dr. Wells because of new diuresis and sodium-correction risk. No automatic urine-for-urine replacement.
Medication Ondansetron 4 mg IV every eight hours PRN nausea or vomiting for 24 hours. PRN Dr. Zoe Langston, MD Active Last given 10/31 at 2012. Next eligible 11/01 at 0412. Expires 11/01 at 2012.
Medication Reconciliation Hold home oral hydrocortisone during IV stress-dose treatment. Immediate Dr. Zoe Langston, MD Active hold No concurrent home doses. Oral transition requires a revised order.
Medication Resume levothyroxine 100 mcg PO every morning at 0800, beginning 11/01, if oral medications tolerated. Continue unless revised. Scheduled Dr. Nadia Wells, MD Active; first resumed dose pending Reviewed with endocrinology. Give on an empty stomach before breakfast. Notify if vomiting prevents administration. Do not increase based on TSH alone.
Monitoring Continuous ECG and pulse oximetry. BP every 30 minutes for two hours, then hourly if stable. Neurologic checks hourly. Continuous / Timed Dr. Nadia Wells, MD Active Replaces initial every-15-minute checks. Notify immediately for MAP <65, confusion, seizure, or focal deficit.
Glucose Monitoring Bedside glucose hourly and PRN symptoms. After rescue treatment, return to frequent checks per treatment order. Hourly / PRN Dr. Nadia Wells, MD Active Next scheduled check 0100. Continue until frequency reassessed.
Laboratory Sodium hourly beginning at 0100. Repeat metabolic panel and paired serum/urine osmolality at 0200. Timed Dr. Nadia Wells, MD Active Replaces every-two-hour sodium schedule. Baseline 118 at 10/31 2003. Goal rise 4–6 mEq/L over 24 hours; avoid >8 mEq/L in any 24 hours.
Provider Notification Notify immediately for sodium β‰₯124 before next review, rise >1 mEq/L between hourly checks, or urine >200 mL/hr for two consecutive hours. Immediate Dr. Nadia Wells, MD Active Do not wait for the maximum correction limit to be exceeded before reporting. Report new neurologic symptoms immediately.
Monitoring / Device Maintain Foley for strict hourly urine measurement during active sodium management. Record all oral and IV intake. Hourly Dr. Nadia Wells, MD Active Foley inserted 10/31 at 2010. Minimum perfusion target approximately 32 mL/hr; excessive output also requires assessment. Review catheter need daily.
Laboratory Initial cortisol, ACTH, thyroid studies, metabolic tests, pregnancy test, and urinalysis. Previously STAT Dr. Zoe Langston, MD Resulted Cortisol and ACTH specimens preceded hydrocortisone. No repeat cortisol ordered during hydrocortisone therapy.
Diet / Activity Measured clear liquids as tolerated. Assisted activity only; fall precautions. Routine / Reassess Dr. Nadia Wells, MD Active Replaces NPO order. Record intake. No automatic fluid restriction or unrestricted water-loading instruction.
Isolation Contact and Standard Precautions for possible infectious gastroenteritis. Ongoing Dr. Zoe Langston, MD Active No further emesis or diarrhea observed. Continue pending clinical and infection-prevention review.
Consultation Endocrinology follow-up and nephrology review for new diuresis and sodium-correction risk. Urgent Dr. Nadia Wells, MD Endocrinology completed; nephrology pending Dr. Fatima Almasi, NP. Dr. Saanvi Reddy, DO, requested at 0010.
Vital Signs and Perfusion Trends
H* and L* indicate values outside the displayed reference or target. High urine output is interpreted with sodium and fluid balance rather than as proof of recovery alone.
Assessment 10/31 β€’ 2000 10/31 β€’ 2105 11/01 β€’ 0000 Reference / Target
Temperature 37.8Β°C / 100.0Β°F H* 37.6Β°C / 99.7Β°F H* 37.2Β°C / 99.0Β°F 36.5–37.5Β°C / 97.7–99.5Β°F
Heart Rate 116/min H* 102/min H* 92/min 60–100/min
Respiratory Rate 22/min H* 20/min 18/min 12–20/min
Blood Pressure 78/44 mmHg L* 92/56 mmHg β€’ Diastolic L* 104/64 mmHg General adult reference: 90–119 / 60–79 mmHg; interpret with MAP and perfusion
Mean Arterial Pressure 55 mmHg L* 68 mmHg 77 mmHg Target β‰₯65 mmHg
SpOβ‚‚ 98% on room air 99% on room air 99% on room air 95–100%
Pain 4/10 β€’ Abdominal discomfort 2/10 β€’ Abdominal discomfort 1/10 β€’ Abdominal discomfort 0–10 scale; individualized comfort goal
Glasgow Coma Scale 14 L* β€’ E3, V5, M6 15 β€’ E4, V5, M6 15 β€’ E4, V5, M6 15
Capillary Refill Approximately 4 seconds H* Approximately 3 seconds H* Approximately 2 seconds ≀2 seconds
Urine Output Not yet measured Initial return 15 mL; additional 20 mL over 55 minutes 60 mL during 2200–2300; 350 mL during 2300–0000 Minimum β‰₯0.5 mL/kg/hr, approximately 32 mL/hr. New high-volume output requires sodium and fluid-balance assessment.
Laboratory Trends
H* = high; L* = low. Post-treatment glucose results are not fasting specimens and are not flagged using a fasting range.
Laboratory Test 10/31 β€’ 2003 10/31 β€’ 2200 11/01 β€’ 0000 Reference / Context
WBC 8.9 Not repeated Not repeated 5–11 Γ— 10Β³/Β΅L
Hemoglobin 13.1 Not repeated Not repeated 12–15 g/dL β€’ Female
Platelets 244 Not repeated Not repeated 150–450 Γ— 10Β³/Β΅L
Sodium 118 L* β€’ Critical 121 L* 122 L* 135–145 mEq/L
Potassium 4.1 3.9 3.8 3.5–5.0 mEq/L
Chloride 86 L* 90 L* 92 L* 95–105 mEq/L
Bicarbonate 20 L* 22 23 22–29 mEq/L
BUN 26 H* 23 H* 20 10–20 mg/dL
Creatinine 1.2 1.0 0.9 0.6–1.2 mg/dL
Serum Glucose 44 mg/dL L* β€’ Critical 90 mg/dL 83 mg/dL Fasting reference 60–100 mg/dL; fasting status unknown. Initial result is hypoglycemic regardless of fasting.
Lactate 2.8 H* 1.6 Not repeated 0.5–2.2 mmol/L
Measured Serum Osmolality 251 L* Not repeated Not repeated; next due 0200 275–295 mOsm/kg
Sodium has increased by 4 mEq/L from baseline in approximately four hours. Continue assessing the cumulative correction over the full 24-hour period.
Endocrine and Urine Results
Test Result / Specimen Time Reference / Interpretation Context
Cortisol 1.2 mcg/dL; pretreatment specimen at 2003 Low in the context of acute illness and established ACTH deficiency. Random values require clinical, timing, and assay interpretation.
ACTH 4 pg/mL L*; pretreatment specimen at 2003 Assay reference 7.2–63.3 pg/mL; interpret with specimen timing and known pituitary disease.
Free T4 0.58 ng/dL L* β€’ Initial specimen 0.8–1.8 ng/dL
TSH 1.1 mIU/L β€’ Initial specimen 0.4–4.0 mIU/L; not a standalone replacement target in central hypothyroidism
Urine Osmolality 110 mOsm/kg β€’ Fresh specimen at 0000 Variable with hydration. Dilute urine; interpret with serum sodium, osmolality, and output.
Urine Specific Gravity 1.003 β€’ Fresh specimen at 0000 Approximately 1.003–1.030; low-end concentration in context of new high-volume urine output
Urinalysis Negative glucose, ketones, leukocyte esterase, and nitrites No glycosuria to explain an osmotic glucose diuresis
Serum Pregnancy Test Negative β€’ Initial specimen Negative
Bedside Glucose Trend
Time Glucose Context
10/31 β€’ 2001 42 mg/dL L* β€’ Critical Before dextrose.
10/31 β€’ 2018 104 mg/dL At completion of initial dextrose.
10/31 β€’ 2033 92 mg/dL Symptoms improving.
10/31 β€’ 2048 88 mg/dL Additional reassessment.
10/31 β€’ 2100 86 mg/dL Hourly monitoring continued.
10/31 β€’ 2200 92 mg/dL No rescue treatment required.
10/31 β€’ 2300 87 mg/dL No recurrent symptoms.
11/01 β€’ 0000 84 mg/dL Next scheduled check 0100.
Diagnostic Studies
  • Initial ECG: Sinus tachycardia without acute ischemic changes. Current telemetry shows sinus rhythm.
  • Pretreatment endocrine specimens: Cortisol 1.2 mcg/dL and ACTH 4 pg/mL. Findings support known central adrenal deficiency in clinical context. No post-hydrocortisone cortisol measurement ordered.
  • Thyroid studies: Low free T4 with non-elevated TSH. Continue management as central hypothyroidism; no acute dose escalation ordered.
  • Urinalysis: No glucose, ketones, leukocyte esterase, or nitrites detected.
  • Fresh urine concentration studies: Osmolality 110 mOsm/kg and specific gravity 1.003 during new high-volume output. These findings alone do not diagnose AVP deficiency.
  • Repeat paired studies: Metabolic panel and serum/urine osmolality scheduled for 0200. Sodium monitoring increased to hourly.
  • Neuroimaging: Not currently ordered. No new severe headache, visual change, seizure, or focal deficit.
Significant Events
  • 10/31 at 2003: Pretreatment blood specimens collected. Dextrose 10% 250 mL started.
  • 10/31 at 2004: Hydrocortisone 100 mg IV given; normal saline 1,000 mL bolus started.
  • 10/31 at 2010: Foley inserted; initial bladder return 15 mL recorded separately.
  • 10/31 at 2012: Ondansetron 4 mg IV given.
  • 10/31 at 2018: Dextrose completed; glucose 104 mg/dL.
  • 10/31 at 2104: Initial saline bolus completed.
  • 10/31 at 2110: Normal saline 100 mL/hr started after provider reassessment.
  • 10/31 at 2130: Transferred to ICU Room 410. Dr. Nadia Wells assumed critical care management.
  • 10/31 at 2200: Sodium 121 mEq/L; lactate 1.6 mmol/L. Bedside glucose 92 mg/dL.
  • 10/31 at 2300: Urine output for preceding hour 60 mL. Bedside glucose 87 mg/dL.
  • 10/31 at 2355: Increasing dilute urine output reported. Dr. Wells reviewed at bedside and discontinued saline infusion.
  • 11/01 at 0000: Sodium 122 mEq/L. Urine output during 2300–0000 totaled 350 mL. BP 104/64 mmHg, MAP 77. GCS 15; bedside glucose 84 mg/dL.
  • 11/01 at 0005: Endocrinology follow-up completed. Hourly sodium monitoring and strict fluid-balance assessment continued.
  • 11/01 at 0010: Nephrology review requested. Next sodium and glucose checks due at 0100. First scheduled maintenance hydrocortisone dose remains due at 0204.
Clinical Judgment

Compare Maya's improving perfusion with her sodium and urine-output trends before answering.

Answer & Rationale

Increased urine output may show improved renal perfusion, but a sudden increase in dilute urine after cortisol replacement can also accelerate sodium correction. Maya's sodium has already increased by 4 mEq/L in approximately four hours, so the remaining correction over the next 20 hours needs close control. The current rise has not exceeded the prescribed maximum, but waiting until that limit is exceeded would miss an opportunity to intervene.

Report the urine-output change promptly, verify the collection interval, and continue strict measurement of all intake and output. Follow the revised hourly sodium schedule, reassess neurologic status and blood pressure, and confirm that the saline infusion was stopped as ordered. Do not independently replace each milliliter of urine with saline or administer desmopressin. These decisions require a specific provider plan based on sodium trajectory, fluid balance, and the cause of the diuresis. Continue essential glucocorticoid treatment.

Answer & Rationale

One high-output hour does not establish arginine vasopressin deficiency, also called central diabetes insipidus. Cortisol replacement and correction of volume depletion can restore water excretion and produce a temporary water diuresis. Assess whether the output persists and interpret it alongside serial serum sodium, serum and urine osmolality, glucose, intake, and volume status. Her normal glucose and absence of glycosuria do not support glucose-driven osmotic diuresis.

Prior pituitary surgery makes AVP deficiency a relevant possibility, and cortisol deficiency can mask its manifestations. Steroid treatment may reveal previously unrecognized partial disease. Persistent hypotonic polyuria or an accelerating sodium rise requires endocrine and nephrology reassessment, but the current findings should not be labeled as a confirmed new diagnosis. Treatment must be individualized because desmopressin can retain water and worsen hyponatremia if used without an appropriate plan.

Please answer both questions before submitting.
1000 Medical Unit β€’ Room 312
This Time, Someone Believed Her

Maya is tolerating meals and oral hormone replacement, with stable blood pressure and a controlled sodium rise. Discharge planning now includes a written steroid plan, a replacement rescue kit, and emergency-injection practice.

11/03/2026 β€’ 1000
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Chief Complaint

β€œI feel like myself again. I need to know exactly what to do if I can't keep my pills down.”

Interval History

Maya is recovering from adrenal crisis associated with an acute vomiting illness and interruption of effective glucocorticoid replacement. Hypotension and hypoglycemia resolved following hydrocortisone, dextrose, and volume replacement. No vasopressor support was required.

The dilute diuresis observed early on 11/01 subsided after the saline infusion was stopped and fluid balance was closely reassessed. Urine output decreased to 170 mL during 0000–0100 and 90 mL during 0100–0200, without desmopressin or electrolyte-free water infusion.

Sodium increased from 118 mEq/L on 10/31 at 2003 to 124 on 11/01 at 2003, a rise of 6 mEq/L during the first 24 hours. It reached 130 on 11/02 at 2003 and is 132 this morning. Reviewed serial measurements remained within the ordered correction limits.

No persistent high-volume hypotonic urine, hypernatremia, or uncontrolled thirst developed. Current findings do not establish arginine vasopressin deficiency. Foley was removed on 11/01 at 1700. She continues to void spontaneously.

IV hydrocortisone was discontinued on 11/02 at 0730 after the final IV dose at 0204. Oral hydrocortisone began at 0800: 20 mg at 0800, 10 mg at 1400, and 10 mg at 2000. She has retained all oral doses and meals.

Levothyroxine 100 mcg PO every morning was resumed on 11/01 after glucocorticoid coverage was established. No dose increase was made during this illness.

Transferred to the medical unit on 11/02 at 0900. No vomiting has occurred since before ED arrival, and no diarrhea developed. Contact Precautions were discontinued on 11/02 at 2200 after infection-prevention review. Standard Precautions continue.

Past Medical History

  • Nonfunctioning pituitary macroadenoma, resected transsphenoidally in 2022.
  • Postoperative ACTH deficiency with secondary adrenal insufficiency.
  • Central hypothyroidism.
  • No established arginine vasopressin deficiency or prior desmopressin treatment.
  • No known diabetes mellitus, heart failure, or chronic kidney disease.

Family History

  • No known familial pituitary disorder or adrenal insufficiency.

Social History

  • Elementary-school librarian.
  • Plans to recover at home with assistance from sister Elena.
  • Identified uncertainty about sick-day dosing and lack of injection practice as barriers to seeking timely treatment.
  • Pharmacy confirms access to prescribed oral replacement and a new emergency kit.

Allergies

Penicillin β€’ hives.

Review of Systems

Constitutional: Mild fatigue; appetite improving. No fever or chills.

Neurologic: No confusion, severe headache, new weakness, speech change, or seizure.

Eyes: No visual change.

Cardiovascular: No dizziness during supervised walking, chest pain, or palpitations.

Respiratory: No dyspnea.

Gastrointestinal: Tolerating meals and medications. No nausea, vomiting, diarrhea, or current abdominal pain.

Genitourinary: Voiding without difficulty. No excessive thirst or unusually large voids.

Physical Examination

General: Awake, comfortable, and participating in education.

Neurologic: GCS 15, oriented Γ—4. Speech clear, strength symmetric, and gait steady during supervised activity.

Cardiovascular: HR 78/min, regular. BP 112/70 mmHg, MAP 84. Extremities warm with capillary refill approximately two seconds.

Respiratory: RR 16/min. Lungs clear. SpOβ‚‚ 99% on room air.

Abdomen: Soft and nontender.

Hydration: Oral mucosa moist. No peripheral edema.

Lines and Devices: One saline-locked peripheral IV remains. Foley absent.

Labs

At 0800: sodium 132 mEq/L, potassium 4.0 mEq/L, chloride 99 mEq/L, bicarbonate 25 mEq/L, BUN 14 mg/dL, creatinine 0.8 mg/dL, and serum glucose 94 mg/dL. Sodium remains mildly below range but is improving at a controlled rate.

No recurrent glucose below 70 mg/dL has been documented since initial treatment. Latest lactate remains the 11/01 result of 1.6 mmol/L; it was not repeated today.

Diagnostics

Repeat paired studies on 11/01 at 0200 showed serum osmolality 259 mOsm/kg and urine osmolality 360 mOsm/kg as urine output declined. These findings and subsequent clinical trends do not support persistent AVP deficiency during this admission.

No new imaging indicated. Repeat free T4 is planned after a consistent replacement interval rather than using an immediate repeat TSH to adjust therapy.

Assessment

  • Adrenal crisis resolved; tolerating oral glucocorticoid replacement.
  • Hypoglycemia resolved without recurrent rescue-treatment requirement.
  • Improving hypotonic hyponatremia without documented excessive correction.
  • Transient dilute diuresis resolved; no confirmed new AVP deficiency.
  • Central hypothyroidism with usual levothyroxine resumed.
  • Vomiting illness resolved; infectious cause not confirmed.
  • Discharge readiness depends on continued oral tolerance, stable repeat sodium, medication access, and successful teach-back.

Plan

  • Continue recovery-dose hydrocortisone: 20 mg PO at 0800, 10 mg at 1400, and 10 mg at 2000 through today's evening dose.
  • On 11/04, resume baseline hydrocortisone 10 mg at 0800 and 5 mg at 1500 only if she remains clinically well, eating normally, and without recurrent vomiting. If still unwell, continue the written stress-dose plan and contact endocrinology that day for instructions.
  • Continue levothyroxine 100 mcg PO every morning on an empty stomach. Recheck free T4 in approximately six weeks after consistent dosing.
  • Repeat sodium at 1400 today. If stable and remaining discharge criteria are met, reassess for discharge. No discharge order has been issued at 1000.
  • Arrange outpatient metabolic panel within 48 hours of discharge. Endocrinology will review the result.
  • Dispense new hydrocortisone emergency kit, verify expiration and supplies, and complete patient/support-person return demonstration.
  • Provide written sick-day and emergency plans, steroid emergency card, and medical-alert guidance.
  • Endocrine telephone review on 11/04; clinic follow-up within one week.
  • Continue measured intake/output while hospitalized. Report recurrent polyuria, excessive thirst, weakness, or vomiting.

Provider Information

Dr. Priya Desai, MD
Internal Medicine

11/03/2026 β€’ 1000
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Nursing Progress Note

Patient awake and oriented Γ—4. Tolerated breakfast and morning oral medications without nausea or vomiting. BP 112/70 mmHg, HR 78/min, RR 16/min, temperature 37.1Β°C / 98.8Β°F, and SpOβ‚‚ 99% on room air. Denies pain or dizziness.

Ambulated in hallway with supervision; gait steady. Voided 450 mL total during 0400–1000, averaging 75 mL/hr. No excessive thirst or abrupt increase in urine output. Peripheral IV remains saline locked without redness or swelling.

Reviewed the difference between baseline hydrocortisone and temporary recovery dosing. Maya correctly identified that today's remaining doses are 10 mg at 1400 and 10 mg at 2000. She explained that baseline dosing resumes tomorrow only if clinically well, according to the written endocrine plan.

Pharmacy supplied an unexpired emergency kit. Using a training device, Maya demonstrated preparation steps and correct IM injection technique. Elena completed a return demonstration. Neither administered an actual rescue dose.

Maya stated, β€œIf I keep throwing up and can't keep my steroids down, I use the emergency injection and get emergency help. I don't wait until I pass out.” Reinforced that emergency injection does not replace emergency medical evaluation.

Written instructions and emergency card reviewed with Maya and Elena. Patient states she will keep the kit accessible rather than leaving it at home during activities. Repeat sodium due at 1400. Discharge remains pending provider reassessment.

11/03/2026 β€’ 0930
Maya Bennett β€’ DOB: 04/17/1990 β€’ MRN: 681429

Endocrinology Follow-Up

Reason for Consultation

Oral replacement transition and prevention planning after adrenal crisis.

Impression

Clinically stable with adequate oral absorption and no recurrent hypoglycemia. Transient water diuresis resolved. Ongoing need for lifelong glucocorticoid replacement remains despite recovery from the acute crisis.

Recommendations

  • Complete today's oral recovery-dose schedule: hydrocortisone 20 mg at 0800, 10 mg at 1400, and 10 mg at 2000.
  • Resume baseline 10 mg at 0800 and 5 mg at 1500 on 11/04 only if recovered and tolerating normal intake. Persistent illness requires continued stress coverage and same-day endocrine advice.
  • For future significant illness when oral medication is retained, use the individualized written sick-day schedule: hydrocortisone 20 mg at 0800, 10 mg at 1400, and 10 mg at 2000 until advised otherwise. Contact the endocrine team for duration and return-to-baseline instructions.
  • Persistent vomiting preventing steroid retention or suspected crisis requires hydrocortisone 100 mg IM from the emergency kit and immediate emergency medical help. Do not rely on repeated oral doses when they cannot be retained.
  • Continue levothyroxine 100 mcg daily. Follow free T4 and clinical status; TSH alone is not a replacement target.
  • Review kit expiration, emergency contacts, medical-alert identification, and adequate medication supply before discharge.

Consulting Provider

Dr. Fatima Almasi, NP
Endocrinology Nurse Practitioner

Nephrology Follow-Up Summary

Dr. Saanvi Reddy, DO, evaluated on 11/01 after the early diuresis. Serial sodium correction remained within the prescribed limits. Desmopressin and electrolyte-free water were not required. Continue planned sodium follow-up; no persistent AVP deficiency established.

Current Provider Orders
Reviewed at 1000 on 11/03/2026. Medication transitions and discontinued emergency treatments remain visible for continuity.
Order Type Order Details Priority Ordered By Status Comments
Level of Care Medical-unit care. Routine Dr. Nadia Wells, MD Transfer completed 11/02 at 0900 Room 312. Current attending: Dr. Priya Desai, MD.
Medication Hydrocortisone PO: 20 mg at 0800, 10 mg at 1400, and 10 mg at 2000. Scheduled Dr. Priya Desai, MD Active through 11/03 at 2000 Recovery dosing began 11/02 at 0800. Today's morning dose retained. Remaining doses due at 1400 and 2000. Reassess before reducing.
Medication / Transition Starting 11/04, hydrocortisone 10 mg PO at 0800 and 5 mg PO at 1500 if clinically recovered and tolerating normal intake. Scheduled / Conditional Dr. Priya Desai, MD Planned; not yet started If still unwell or vomiting recurs, do not reduce automatically. Follow written stress-dose plan and obtain same-day endocrine instructions. Long-term replacement; do not stop abruptly.
Medication Levothyroxine 100 mcg PO every morning at 0800 on an empty stomach. Scheduled Dr. Nadia Wells, MD Active Resumed 11/01 after steroid coverage. Continue long term unless revised. Separate from iron/calcium supplements by at least four hours.
Discharge Prescription Hydrocortisone sodium succinate 100 mg IM emergency kit for suspected adrenal crisis or persistent vomiting preventing oral steroid retention. Before discharge Dr. Priya Desai, MD Dispensed; teaching completed Use as trained and obtain emergency medical help immediately. No rescue dose administered today. Verify diluent, supplies, expiration, and replacement process after use.
Laboratory Repeat sodium today at 1400. Timed Dr. Priya Desai, MD Pending Discharge requires review of result and continued clinical stability.
Outpatient Laboratory Metabolic panel within 48 hours after discharge. Timed follow-up Dr. Priya Desai, MD Ordered Endocrinology to review sodium, renal function, and electrolytes. Confirm collection arrangements before leaving.
Outpatient Laboratory Free T4 approximately six weeks after consistent levothyroxine dosing. Follow-up Dr. Priya Desai, MD Planned Central hypothyroidism: do not titrate solely to TSH.
Monitoring Vital signs and neurologic checks every four hours. Bedside glucose before meals and at bedtime while hospitalized; PRN symptoms. Scheduled / PRN Dr. Priya Desai, MD Active Replaces ICU monitoring frequency. Report glucose <70 mg/dL, hypotension, confusion, or new weakness. Treat symptomatic hypoglycemia promptly under the hospital emergency protocol.
Monitoring Measure each void and record shift intake/output. Ongoing Dr. Priya Desai, MD Active Report reduced output, recurrent high-volume urine, or excessive thirst. No Foley currently indicated.
Diet / Activity Regular diet and oral fluids as tolerated. Ambulation with assistance as needed. Routine Dr. Priya Desai, MD Active Replaces measured clear-liquid order. Continue intake documentation. Assess dizziness before activity.
Isolation Standard Precautions. Ongoing Dr. Priya Desai, MD Active Contact Precautions discontinued 11/02 at 2200 after infection-prevention review and more than 48 hours without vomiting or diarrhea.
Education Written baseline, recovery, sick-day, and emergency-injection plans. Teach-back and injection return demonstration. Before discharge Dr. Priya Desai, MD Completed; reinforce before departure Maya and Elena demonstrated using training equipment. Emergency card supplied. Medical-alert identification encouraged.
Follow-Up Endocrine telephone review 11/04; clinic review within one week. Before discharge Dr. Priya Desai, MD Arrangements in progress Dr. Fatima Almasi, NP. Confirm contact number and appointments in written discharge instructions.
Medication Hydrocortisone 100 mg IV once. Previously STAT Dr. Zoe Langston, MD Given 10/31 at 2004 Completed emergency dose.
Medication Hydrocortisone 50 mg IV every six hours. Previously scheduled Dr. Zoe Langston, MD Discontinued 11/02 at 0730 Last IV dose 11/02 at 0204. Oral therapy began at 0800. No duplicate IV and oral maintenance orders.
Medication Dextrose 10% 250 mL IV once. Previously STAT Dr. Zoe Langston, MD Completed 10/31 at 2018 Initial 25 g dextrose treatment.
Medication / Rescue Initial 24-hour dextrose rescue order. Previously PRN Dr. Zoe Langston, MD Expired 11/01 at 2000 No repeat rescue doses were required. Expired order is not an active PRN.
Medication Ondansetron 4 mg IV every eight hours PRN for 24 hours. Previously PRN Dr. Zoe Langston, MD Expired 11/01 at 2012 No current antiemetic requirement.
IV Fluid Normal saline 1,000 mL bolus, then 100 mL/hr after reassessment. Previously STAT / Routine Dr. Zoe Langston, MD Bolus completed 10/31 at 2104; infusion stopped at 2355 Not restarted. No desmopressin or electrolyte-free water infusion was required.
Procedure Remove Foley catheter. Routine Dr. Nadia Wells, MD Completed 11/01 at 1700 Voiding spontaneously afterward.
Discharge Reassess after repeat sodium, medication-access verification, and final education review. Conditional assessment Dr. Priya Desai, MD No discharge order yet Do not remove IV or discharge before provider clearance.
Vital Signs and Perfusion Trends
H* and L* identify values outside the displayed reference or target. Urine-output intervals are stated explicitly.
Assessment 10/31 β€’ 2000 11/01 β€’ 0000 11/03 β€’ 1000 Reference / Target
Temperature 37.8Β°C / 100.0Β°F H* 37.2Β°C / 99.0Β°F 37.1Β°C / 98.8Β°F 36.5–37.5Β°C / 97.7–99.5Β°F
Heart Rate 116/min H* 92/min 78/min 60–100/min
Respiratory Rate 22/min H* 18/min 16/min 12–20/min
Blood Pressure 78/44 mmHg L* 104/64 mmHg 112/70 mmHg General adult reference: 90–119 / 60–79 mmHg; interpret with MAP and perfusion
Mean Arterial Pressure 55 mmHg L* 77 mmHg 84 mmHg Target β‰₯65 mmHg
SpOβ‚‚ 98% on room air 99% on room air 99% on room air 95–100%
Pain 4/10 β€’ Abdominal discomfort 1/10 β€’ Abdominal discomfort 0/10 0–10 scale; individualized comfort goal
Glasgow Coma Scale 14 L* β€’ E3, V5, M6 15 β€’ E4, V5, M6 15 β€’ E4, V5, M6 15
Capillary Refill Approximately 4 seconds H* Approximately 2 seconds Approximately 2 seconds ≀2 seconds
Urine Output Not measured at arrival. Initial Foley return later: 15 mL; subsequent 20 mL over 55 minutes. 60 mL during 2200–2300, then 350 mL during 2300–0000 450 mL over six hours, 0400–1000; average 75 mL/hr, spontaneous voids Minimum β‰₯0.5 mL/kg/hr, approximately 32 mL/hr. Assess excessive output with sodium and fluid balance.
Laboratory Trends
Current blood specimens collected 11/03 at 0800. H* = high; L* = low. Post-treatment glucose values are not flagged using a fasting reference when fasting is unconfirmed.
Laboratory Test 10/31 β€’ 2003 11/01 β€’ 0000 11/03 β€’ 0800 Reference / Context
Sodium 118 L* β€’ Critical 122 L* 132 L* 135–145 mEq/L
Potassium 4.1 3.8 4.0 3.5–5.0 mEq/L
Chloride 86 L* 92 L* 99 95–105 mEq/L
Bicarbonate 20 L* 23 25 22–29 mEq/L
BUN 26 H* 20 14 10–20 mg/dL
Creatinine 1.2 0.9 0.8 0.6–1.2 mg/dL
Serum Glucose 44 mg/dL L* β€’ Critical 83 mg/dL 94 mg/dL Fasting reference 60–100 mg/dL; fasting status unconfirmed. Initial result represents hypoglycemia regardless of fasting.
Lactate 2.8 H* Not repeated at this time Not repeated 0.5–2.2 mmol/L. Latest: 1.6 on 10/31 at 2200.
WBC 8.9 Not repeated Not repeated 5–11 Γ— 10Β³/Β΅L
Hemoglobin 13.1 Not repeated Not repeated 12–15 g/dL β€’ Female
Platelets 244 Not repeated Not repeated 150–450 Γ— 10Β³/Β΅L
Sodium Correction Checkpoints
Selected checkpoints from the more frequent inpatient measurements. Interval changes are not substitutes for reviewing the full serial trend.
Specimen Time Sodium Change / Context
10/31 β€’ 2003 118 mEq/L L* Baseline before treatment.
10/31 β€’ 2200 121 mEq/L L* +3 from baseline.
11/01 β€’ 0000 122 mEq/L L* +4 from baseline; monitoring intensified during diuresis.
11/01 β€’ 0200 123 mEq/L L* Urine output declining.
11/01 β€’ 0800 123 mEq/L L* No continued rapid rise.
11/01 β€’ 2003 124 mEq/L L* +6 during the first 24 hours.
11/02 β€’ 0800 126 mEq/L L* Continued controlled improvement.
11/02 β€’ 2003 130 mEq/L L* +6 during the second 24-hour interval.
11/03 β€’ 0800 132 mEq/L L* Repeat due at 1400 before discharge review.
Endocrine and Paired Osmolality Results
Test Result Specimen / Interpretation Context
Cortisol 1.2 mcg/dL Pretreatment 10/31 at 2003. Low in acute illness with known ACTH deficiency. Not repeated during hydrocortisone treatment.
ACTH 4 pg/mL L* Pretreatment specimen. Assay reference 7.2–63.3 pg/mL; interpret with timing and pituitary history.
Free T4 0.58 ng/dL L* Initial result; reference 0.8–1.8. Not repeated during this recovery assessment.
TSH 1.1 mIU/L Initial result; reference 0.4–4.0. Not a standalone replacement target in central hypothyroidism.
Paired Serum Osmolality 259 mOsm/kg L* 11/01 at 0200; reference 275–295 mOsm/kg.
Paired Urine Osmolality 360 mOsm/kg 11/01 at 0200. Increased from 110 at 0000 as transient diuresis subsided.
Urinalysis Negative glucose, ketones, leukocyte esterase, and nitrites Previously resulted; not repeated.
Diagnostic Studies
  • Initial ECG: Sinus tachycardia without acute ischemic changes. No subsequent clinically significant rhythm disturbance. Continuous ICU telemetry has been discontinued.
  • Pretreatment endocrine studies: Low cortisol and ACTH support established central adrenal deficiency in context. No repeat cortisol ordered during replacement therapy.
  • Paired osmolality studies on 11/01 at 0200: Serum osmolality 259 mOsm/kg; urine osmolality 360 mOsm/kg. Urine concentration increased as output normalized.
  • Serial sodium monitoring: Controlled improvement without documented excessive correction. Current sodium 132 mEq/L. Repeat at 1400 remains pending.
  • Thyroid follow-up: Free T4 reassessment planned after approximately six weeks of consistent levothyroxine. No acute TSH-driven dose escalation.
  • Neuroimaging: Not ordered during the current course. No new severe headache, visual loss, seizure, or focal deficit.
Significant Events
  • 10/31 at 2004: Initial hydrocortisone 100 mg IV administered.
  • 10/31 at 2355: Saline infusion stopped during assessment of new dilute diuresis.
  • 11/01 at 0010: Nephrology review requested. Dr. Saanvi Reddy subsequently evaluated sodium trajectory and fluid balance.
  • 11/01 at 0200: Sodium 123 mEq/L. Urine output and urine concentration improving. Desmopressin and electrolyte-free water were not required.
  • 11/01 at 0204: First scheduled hydrocortisone 50 mg IV maintenance dose administered.
  • 11/01 at 0800: Levothyroxine 100 mcg PO resumed after established steroid coverage.
  • 11/01 at 1700: Foley removed. Subsequent spontaneous voids measured.
  • 11/01 at 2000: Initial 24-hour dextrose rescue order expired.
  • 11/01 at 2003: Sodium 124 mEq/L: increase of 6 during the first 24 hours.
  • 11/01 at 2012: Ondansetron order expired without ongoing need.
  • 11/02 at 0204: Final IV hydrocortisone dose administered.
  • 11/02 at 0730–0800: IV hydrocortisone discontinued; oral recovery dosing initiated and retained.
  • 11/02 at 0900: Transferred to Medical Unit Room 312.
  • 11/02 at 2003: Sodium 130 mEq/L: increase of 6 during the second 24-hour interval.
  • 11/02 at 2200: Contact Precautions discontinued after review. Standard Precautions continued.
  • 11/03 at 0800: Sodium 132 mEq/L. Morning oral hydrocortisone and levothyroxine administered and retained.
  • 11/03 at 0930: Endocrinology reviewed recovery dosing, conditional return to baseline, and emergency plan.
  • 11/03 at 1000: Maya and Elena completed injection return demonstrations using training equipment. New emergency kit supplied. Repeat sodium due at 1400; discharge remains pending.
Clinical Judgment

Review Maya's response to treatment, oral medication transition, and emergency plan.

Answer & Rationale

Maya has stable blood pressure, normal mental status, adequate spontaneous urine output, and no recurrent hypoglycemia. She is tolerating meals and oral medications without vomiting. Sodium has improved with controlled correction, although it remains below the displayed reference range. Review the pending repeat sodium, continued oral tolerance, medication access, and the provider's discharge decision before she leaves.

The earlier dilute diuresis resolved without desmopressin, and urine concentration increased as output declined. This supports a transient recovery-related water diuresis rather than establishing persistent AVP deficiency. Pituitary history still makes recurrent polyuria and excessive thirst important to report. Discharge also requires a clear steroid schedule, confirmed follow-up and laboratory arrangements, an accessible rescue kit, and successful teach-back. Improved symptoms do not eliminate her lifelong need for glucocorticoid replacement.

Answer & Rationale

Extra oral medication cannot reliably protect Maya when persistent vomiting prevents absorption. If she cannot retain steroids or develops signs of adrenal crisis, she should use the prescribed 100 mg IM emergency hydrocortisone and obtain emergency medical help immediately. The injection is an emergency bridge, not permission to continue an activity or stay home. When oral medication is retained during illness, she follows her individualized written stress-dose schedule and contacts endocrinology for guidance.

Elena should know where the kit is kept, how to prepare and administer it, and how to obtain emergency assistance. Confirm current supplies, expiration, replacement after use, and medical-alert identification. Maya should distinguish today's temporary recovery regimen from her baseline schedule and avoid reducing doses while still unwell. Levothyroxine remains important, but it does not replace cortisol and should not be independently increased to treat acute weakness. Use teach-back and return demonstration to verify that the plan can be carried out.

Please answer both questions before submitting.